Since antithrombin is a key hemostatic element and the target of heparin, which acts as a cofactor leading to its conformational activation, we speculated that the paraprotein of patients with plasma cell disorders might also target this anticoagulant. This hypothesis was evaluated in a 73-years old woman with monoclonal gammopathy of undetermined significance that progressed to a quiescent multiple myeloma IgG-λ (2.5 g/L).
Since the diagnosis, the patient had multiple bleeding events in arms and legs appearing spontaneously or after mild traumatisms. When the disease progressed, she developed Platelet function assay (PFA) studies, coagulation assays and analysis of coagulation factors were done but only revealed a prolonged thrombin time (> 180s) and aPTT (75-97 sec, ratio 2.59-3.13) at all tested time points, including the moment of the severe hemorrhage and after treatment. Interestingly, the thrombin time was corrected by protamine in vitro (Table 1) , and the reptilase time was always normal. The neutralization of heparin-induced bleeding by protamine sulfate 7 supports the presence of a molecule with a heparin-like effect in this patient. Aiming to identify this factor and to clarify the mechanism underlying the bleeding event of this patient, plasma proteins able to bind antithrombin were purified following the strategy shown in Figure 1A . This procedure revealed a main protein that was recognized by an anti-IgG polyclonal antibody ( Figure 1) . After a last protein purification step of anionic exchange, mass spectrometry proteomic analysis verified that the protein purified was an IgG isotype Further studies are required to verify this hypothesis, and to find the potential differences that might have prognostic relevance in patients with myeloma and related plasma cell disorders.
Finally, we can't forget that the interference on the thrombin-antithrombin axis may also affect the risk of thrombosis. The binding of certain IgGs to the heparin binding domain of antithrombin might impair the activation of antithrombin by physiological cofactors when it is required, thus also contributing to the risk of thrombosis, which is also a relatively frequent complication in these disorders. 13 Purification following our procedure and analysis of the IgG of patients with myeloma and related plasma cell disorders who develop thrombosis may help to answer this question. 
